Han Woong Lee

Title: Han Woong Lee: Innovator in Cancer Drug Resistance

Introduction

Han Woong Lee is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of cancer research, particularly in understanding drug resistance mechanisms. His innovative work focuses on the EI24 gene and its implications for improving the efficacy of anti-cancer drugs.

Latest Patents

Han Woong Lee holds a patent related to the use of the EI24 gene. The patent describes a novel application of EI24 in improving resistance to EGFR-TKI drugs by inhibiting IGF-1R signaling. This groundbreaking research indicates that the expression level of EI24 can be used to determine resistance to anti-cancer drugs. Furthermore, the patent outlines methods to inhibit, delay, or improve drug resistance through the use of EI24 or its activating agents. By regulating the EI24-mediated resistance pathway, the effectiveness of existing anti-cancer treatments can be enhanced.

Career Highlights

Han Woong Lee is affiliated with Yonsei University, where he conducts his research. His work has garnered attention for its potential to transform cancer treatment strategies. With a focus on molecular biology and genetics, he continues to explore innovative solutions to combat drug resistance in cancer therapies.

Collaborations

Han Woong Lee collaborates with esteemed colleagues, including Jung-Min Choi and Byoung Chul Cho. Their combined expertise contributes to advancing research in cancer treatment and drug resistance.

Conclusion

Han Woong Lee's contributions to cancer research, particularly through his patent on the EI24 gene, highlight his role as an innovator in the field. His work promises to enhance the effectiveness of anti-cancer drugs and offers hope for improved treatment outcomes.